Sensei Biotherapeutics (NASDAQ:FTH) Issues Quarterly Earnings Results

Sensei Biotherapeutics (NASDAQ:FTH) announced its quarterly earnings data on Tuesday. The company reported ($0.62) earnings per share (EPS) for the quarter, topping the consensus estimate of ($5.04) by $4.42, FiscalAI reports.

Sensei Biotherapeutics Stock Performance

Shares of Sensei Biotherapeutics stock opened at $25.06 on Tuesday. The firm has a market cap of $33.63 million, a PE ratio of -0.17 and a beta of -0.26. Sensei Biotherapeutics has a 12 month low of $7.20 and a 12 month high of $37.90.

Insider Buying and Selling

In other Sensei Biotherapeutics news, CFO Brian C. Stephenson bought 5,000 shares of the company’s stock in a transaction on Wednesday, July 1st. The shares were bought at an average cost of $23.50 per share, for a total transaction of $117,500.00. Following the acquisition, the chief financial officer directly owned 46,688 shares in the company, valued at approximately $1,097,168. The trade was a 11.99% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, major shareholder James Peyer sold 25,000 shares of the stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $20.02, for a total transaction of $500,500.00. Following the transaction, the insider owned 130,142 shares in the company, valued at approximately $2,605,442.84. The trade was a 16.11% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders acquired a total of 49,494 shares of company stock valued at $1,188,822 over the last three months. 7.00% of the stock is owned by company insiders.

Hedge Funds Weigh In On Sensei Biotherapeutics

A hedge fund recently raised its stake in Sensei Biotherapeutics stock. Renaissance Technologies LLC raised its stake in shares of Sensei Biotherapeutics, Inc. (NASDAQ:FTH) by 10.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 11,516 shares of the company’s stock after acquiring an additional 1,100 shares during the quarter. Renaissance Technologies LLC owned approximately 0.91% of Sensei Biotherapeutics worth $123,000 at the end of the most recent reporting period. 10.50% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

FTH has been the subject of a number of research analyst reports. Loop Capital set a $50.00 price target on Sensei Biotherapeutics in a research note on Thursday, May 28th. Zacks Research upgraded shares of Sensei Biotherapeutics to a “hold” rating in a report on Tuesday, April 21st. Robert W. Baird assumed coverage on shares of Sensei Biotherapeutics in a research note on Friday, June 26th. They issued an “outperform” rating and a $57.00 price target on the stock. Leerink Partners initiated coverage on shares of Sensei Biotherapeutics in a report on Monday, April 20th. They set an “outperform” rating and a $50.00 price objective for the company. Finally, Citizens Jmp assumed coverage on shares of Sensei Biotherapeutics in a research report on Monday, July 20th. They set an “outperform” rating and a $51.00 target price on the stock. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Sensei Biotherapeutics presently has an average rating of “Moderate Buy” and an average price target of $54.89.

About Sensei Biotherapeutics

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.

The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.